Briefs

Highlights from the 2008 Conference

COMPILED FROM STAFF REPORTS

Doctors and advocates came away from the 2008 San Antonio Breast Cancer Symposium with answers to a number of important questions: Can patients make the switch from an aromatase inhibitor to tamoxifen without sacrificing efficacy? Is the combination of Tykerb (lapatinib) and Femara (letrozole) better than Femara alone? What's the best schedule for giving taxanes? And what new agents are having success against breast cancer?...[MORE]

Personalizing Prevention of Invasive Breast Cancer

BY MELISSA WEBER

By identifying women at low risk for breast cancer, resources can be redirected to high-risk women, thus lowering the incidence of breast cancer, said Jack Cuzick, PhD, on Wednesday during an education session...[MORE]

Blogs

DEBU TRIPATHY, MD

What To Expect in 2009 at SABCS

The 32nd San Antonio Breast Cancer Symposium has a slightly different flavor this year—more definitive trial data that will influence how we take care of breast cancer. Last year happened to be a time when... [MORE]

KATHY LATOUR

A Meeting Filled with Hope and Promise

The San Antonio Breast Cancer Symposium kicked off Wednesday with some pre-meeting sessions, but mostly those attending were picking up their badges... [MORE]

SUSAN MCCLURE

The 32nd annual SABCS gets under way

On November 11, 1978, a group of 141 physicians and surgeons from a five state area got together during Breast Cancer Awareness Week to discuss ways to... [MORE]

BEV PARKER

SABCS From an Advocate's Perspective

This is the 34th annual San Antonio Breast Cancer Symposium, and the seventh I've attended. I was lucky to escape Chicago today while a big winter storm was moving in... [MORE]

Message Board

Are you involved in advocacy? Share your story of advocacy accomplishments on the CURE Message Board.

PROFILE:

Helping Women and Men Survive Breast Cancer

BY KATHY LATOUR

Since her diagnosis in 1985 at the age of 40, Bev Parker has been there for women—and men—diagnosed with breast cancer. She began working as... [MORE]

Become a fan of CURE on Facebook.

Follow CURE on Twitter.

Send feedback to editor@curetoday.com.

Sign up for our e-mail newsletters, which you can now personalize by tumor type, survivorship, or caregiver status.

This e-mail was sent to you because you have provided your e-mail address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

Please add enews@curetoday.com to your address book or safe sender list to ensure this e-mail is delivered to your inbox.

2009 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic, or treatment advice.